ZALTRAP (ziv-aflibercept)
ANTINEOPLASTIC-VEGF-A AND B,PLGF GROWTH FACTOR INHIBITOR · METASTATIC COLORECTAL CANCER
Sanofi-Aventis U.S.
Drug class
Antineoplastic-VEGF-A and B,PlGF Growth Factor Inhibitor
Although the exact phrase "Antineoplastic-VEGF-A and B,PlGF Growth Factor Inhibitor" represents a highly specific descriptive or compendial classification phrase rather than a standard FDA Established Pharmacologic Class, it refers to recombinant decoy fusion proteins—exemplified by systemic ziv-aflibercept—categorized by regulatory authorities under vascular endothelial growth factor inhibitors. Read more about Antineoplastic-VEGF-A and B,PlGF Growth Factor Inhibitor
1 drugs in this class 1 manufacturers
Drugs in Antineoplastic-VEGF-A and B,PlGF Growth Factor Inhibitor
Filter & compare in the drug finder →
Opens the drug finder with Antineoplastic-VEGF-A and B,PlGF Growth Factor Inhibitor preselected. Add indication or manufacturer filters there.
Although the exact phrase "Antineoplastic-VEGF-A and B,PlGF Growth Factor Inhibitor" represents a highly specific descriptive or compendial classification phrase rather than a standard FDA Established Pharmacologic Class, it refers to recombinant decoy fusion proteins—exemplified by systemic ziv-aflibercept—categorized by regulatory authorities under vascular endothelial growth factor inhibitors.
Agents in this group function as soluble decoy receptors engineered from human VEGF receptor extracellular domains fused to an IgG1 Fc fragment, enabling them to bind circulating VEGF-A, VEGF-B, and placental growth factor with high affinity.
By sequestering these angiogenic ligands, the drug prevents receptor activation and downstream signaling, thereby suppressing pathological tumor angiogenesis and vascular permeability.
In oncology, this therapeutic approach is primarily indicated in combination with chemotherapy regimens for adults with metastatic colorectal cancer that is resistant to or has progressed after oxaliplatin-based therapy.
-
fda.gov
Although the exact phrase "Antineoplastic-VEGF-A and B,PlGF Growth Factor Inhibitor" represents a highly specific descriptive or compendial classification phrase rather than a standard FDA Established Pharmacologic Class, it refers to recombinant decoy fusion proteins—exemplified by systemic ziv-aflibercept—categorized by regulatory authorities under vascular endothelial growth factor inhibitors Agents in this group function as soluble decoy receptors engineered from human VEGF receptor extracel...
-
ndclist.com
Although the exact phrase "Antineoplastic-VEGF-A and B,PlGF Growth Factor Inhibitor" represents a highly specific descriptive or compendial classification phrase rather than a standard FDA Established Pharmacologic Class, it refers to recombinant decoy fusion proteins—exemplified by systemic ziv-aflibercept—categorized by regulatory authorities under vascular endothelial growth factor inhibitors
-
nih.gov
Agents in this group function as soluble decoy receptors engineered from human VEGF receptor extracellular domains fused to an IgG1 Fc fragment, enabling them to bind circulating VEGF-A, VEGF-B, and placental growth factor with high affinity
-
fda.gov
In oncology, this therapeutic approach is primarily indicated in combination with chemotherapy regimens for adults with metastatic colorectal cancer that is resistant to or has progressed after oxaliplatin-based therapy
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.